Scientist on Baby KJ team launches new CRISPR startup
In the midst of savoring slices of mouth-watering pizza at Pizzeria da Laura in Berkeley, gene editing expert Fyodor Urnov and venture capitalist Johnny Hu found themselves brainstorming a groundbreaking concept for a revolutionary CRISPR company.
The year was 2024, and Urnov, a distinguished professor at the University of California, Berkeley, had been fervently advocating for the potential of CRISPR technology in treating patients with rare genetic mutations. His impassioned lectures and writings underscored the immense possibilities that CRISPR held, provided that regulatory bodies and corporations embraced its potential. On the other hand, Hu, armed with a Ph.D. in gene editing and experience as a principal at Menlo Ventures, was keen on leveraging his expertise to contribute to this transformative field.
As they indulged in their meal, a spark of inspiration ignited a conversation that would shape the future of genetic medicine. Urnov and Hu contemplated the feasibility of their vision, pondering on how to translate their shared belief in the capabilities of CRISPR into a thriving business venture.
“Johnny posed a question that resonated with me,” Urnov recounted. “He asked, ‘how realistic is any of this?’ I turned to him and replied, ‘from a technological standpoint, we are in agreement that this is achievable. However, the real challenge lies in building a sustainable company that can truly succeed.’”
Their discussion delved into the intricate intersection of science, entrepreneurship, and innovation. The prospect of harnessing CRISPR to address rare genetic disorders was not just a theoretical concept but a tangible opportunity waiting to be seized. With their expertise and determination, Urnov and Hu envisioned a future where precision medicine could be accessible to those in need, paving the way for a new era of genetic therapeutics.
The meeting of minds at Pizzeria da Laura marked the genesis of a transformative journey that would culminate in the birth of Aurora Therapeutics, a pioneering startup poised to redefine the landscape of genetic medicine. As they polished off the last crumbs of their pizza, Urnov and Hu knew that their collaboration would not only change lives but also shape the future of healthcare in ways they had only dared to imagine.
